Navigation Links
Bone Drugs May Beat Back Breast Cancer
Date:12/10/2009

Bisphosphonates seem to prevent recurrence, researchers find

THURSDAY, Dec. 10 (HealthDay News) -- Bone-building drugs used by tens of millions of women to fight osteoporosis also cut the risk of breast cancer, suggesting the drugs may play a dual role in keeping women healthy.

"Bone loss and potential fractures are a known complication of breast cancer therapy. Our feeling is that bisphosphonates may actually prevent disease recurrence through a variety of mechanisms," said Dr. Adam Brufsky, associate director of clinical investigation at the University of Pittsburgh Cancer Institute.

Brufsky authored one of several studies exploring the role of bone-building drugs in breast cancer prevention that were to be presented Thursday at the San Antonio Breast Cancer Symposium.

Bisphosphonates are already used to treat complications that result from breast cancer spreading to the bones.

One study looked at more than 150,000 postmenopausal women who participated in the U.S. government-led Women's Health Initiative (WHI).

The women taking bisphosphonates, namely Fosamax (alendronate), had a 32 percent reduction in their rate of invasive breast cancer compared to women who were not taking one of these drugs.

The University of California, Los Angeles, researchers were able to control for the fact that women with low bone mineral density are already at lower risk for breast cancer.

Because the study was not a randomized, controlled one, said lead investigator Dr. Rowan Chlebowski, a professor and medical oncologist with UCLA, "the findings are not definitive but they do provide a strong signal."

In another study, Israeli researchers found that postmenopausal women taking bisphosphonates for one or more years had a 29 percent reduction in their risk of breast cancer.

And the tumors that did appear tended to be estrogen receptor-positive and thus easier to treat than estrogen receptor-negative tumors.

And in other news from the symposium:

  • Researchers from the University of Pittsburgh Cancer Institute, led by Brufsky, concluded that zoledronic acid, another bisphosphonate, is safe and effective for use by postmenopausal women with breast cancer who are being treated with aromatase inhibitors. Bone mineral density increased 6.2 percent in women taking zoledronic acid, compared with 2.4 percent in the control group. Fractures were also reduced slightly in the treatment group, but it's unclear how significant this was. Zoledronic acid is marketed under several brand names, including Zometa.
  • A new drug, denosumab, a monoclonal antibody, performed better than zoledronic acid in easing problems associated with the spread of breast cancer to the bones.
  • A final study found that it was safe to give zoledronic acid to women with breast cancer being treated with the aromatase inhibitor Femara (letrozole) before surgery. No clear indication emerged as to whether the dual treatment was effective, however.

More information

The National Cancer Institute has more on breast cancer.



SOURCES: Dec. 9, 2009, teleconference with: Rowan Chlebowski, M.D., Ph.D., medical oncologist, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center, and Adam Brufsky, M.D., Ph.D., associate professor, medicine, associate chief, hematology-oncology, and associate director, clinical investigation, University of Pittsburgh Cancer Institute


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. AIDS Drugs Dont Need Routine Lab Monitoring
2. Statement of HDMA President and CEO John M. Gray on the Importation of Prescription Drugs
3. Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs
4. OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable
5. Second-line CML drugs evoke faster response than front-line therapy
6. Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
7. Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
8. Diabetes Drugs Go Head-to-Head in Study
9. drugstore.com Continues Global Sales Expansion to More Than 3.5 Billion International Consumers
10. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
11. Coverage of inexpensive drugs may increase length and quality of life after heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology: